NCT03717909View on ClinicalTrials.gov

Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2024

Conditions
Wolfram Syndrome
Interventions
DRUG

Sodium Valproate 200Mg E/C Tablet

Treatment with twice-daily oral tablet(s)

DRUG

Sodium Valproate matched placebo

Treatment with twice-daily oral 200mg tablet(s)

Trial Locations (6)

34295

CHU de Montpellier, Hopital Gui de Chauliac, Montpellier

75015

Hôpital Européen Georges-Pompidou, Paris

91-738

Medical University of Lodz, Lodz

04120

Unidad de Gestión Clínica Almería Periferia. Distrito Sanitario Almería, Almería

B15 2TH

University Hospitals Birmingham, Birmingham

B4 6NH

Birmingham Women's and Children's Hospital, Birmingham

All Listed Sponsors
lead

University of Birmingham

OTHER

NCT03717909 - Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome | Biotech Hunter | Biotech Hunter